Suven Life Sciences has informed that it enclosed News Release of the company titled ‘Suven Life Sciences Reports Positive DSMB Safety Review and Interim Analysis from Ongoing Global Phase 3 Study of Masupirdine in Alzheimer's Disease Agitation at 50% study completers - Study to Continue Unchanged’.
The above information is a part of company’s filings submitted to BSE.